Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Round Table Discussions
Sign in
Join now
featured
Published in Oncology and
2 other channels

Journal Scan / Research · September 23, 2020

Quality of Life in Patients With Metastatic Prostate Cancer Following Treatment With Cabazitaxel vs Abiraterone or Enzalutamide

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Paul Hampel MD

Oliver Sartor MD

The Lancet Oncology
Quality of Life in Patients With Metastatic Prostate Cancer Following Treatment With Cabazitaxel Versus Abiraterone or Enzalutamide (CARD): An Analysis of a Randomised, Multicentre, Open-Label, Phase 4 Study
Lancet Oncol 2020 Sep 11;[EPub Ahead of Print], K Fizazi, G Kramer, JC Eymard, CN Sternberg, J de Bono, D Castellano, B Tombal, C Wülfing, M Liontos, J Carles, R Iacovelli, B Melichar, Á Sverrisdóttir, C Theodore, S Feyerabend, C Helissey, S Oudard, G Facchini, EM Poole, A Ozatilgan, C Geffriaud-Ricouard, S Bensfia, R de Wit

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Most Read This Week

Recently Updated